4//SEC Filing
Jamil Khurram 4
Accession 0001133416-26-000004
CIK 0001133416other
Filed
Jan 5, 7:00 PM ET
Accepted
Jan 6, 4:53 PM ET
Size
13.0 KB
Accession
0001133416-26-000004
Insider Transaction Report
Form 4
Jamil Khurram
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2026-01-02+60,000→ 60,000 total - Sale
Common Stock
2026-01-02$4.20/sh−13,055$54,789→ 46,945 total - Sale
Common stock
2026-01-05$3.90/sh−25,499$99,408→ 21,446 total - Sale
Common Stock
2026-01-06$3.65/sh−21,446$78,205→ 0 total - Exercise/Conversion
Restricted Stock Unit
2026-01-01−60,000→ 0 totalExercise: $0.00From: 2026-01-02→ Common Stock (60,000 underlying)
Footnotes (6)
- [F1]The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.
- [F2]The shares were sold in multiple transactions at prices ranging from $4.00 to $4.34. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- [F3]Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units.
- [F4]Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026.
- [F5]The shares were sold in multiple transactions at prices ranging from $3.81 to $4.06. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- [F6]The shares were sold in multiple transactions at prices ranging from $3.81 to $3.42. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Documents
Issuer
GALECTIN THERAPEUTICS INC
CIK 0001133416
Entity typeother
Related Parties
1- filerCIK 0002032345
Filing Metadata
- Form type
- 4
- Filed
- Jan 5, 7:00 PM ET
- Accepted
- Jan 6, 4:53 PM ET
- Size
- 13.0 KB